p < 0,05), increase of EF by 2,5% (p < 0,05) were accompanied with decrease of LVMI by 12,2% (p < 0,05). 12-month treatment with combination ramipril and lercanidipine didn't influenced on TC, LDL-C, HDL-C levels, but TG level had statistically significant decrease by 12,9% (p < 0,05), that became correspondent to recommended level for patients without type 2 diabetes -1,80 mmol/l. Level of fasting glucose in blood serum hadn't exposed to statistically significant changes.Conclusions: Hipotensive effect of ramipril 5 mg and lercanidipine 10 mg/ daily in hypertensive patients with CAD and type 2 diabetes accompanies with left ventricular hypertrophy's regression, decrease of numbers of angina pectoris attacks, need in sublingual Nitroglycerine. This combination hasn't caused negative effect on lipid and carbohydrate metabolism, but promotes decrease of manifestation of diabetic dyslipidemia and can be approved not only as treating agent but also as preventive medications in such patients.Objective: To evaluate the effects on Diabetic Retinopathy (DR) of a multifactorial therapeutic regimen based on 32 mg BID Candesartan during a 30 months period of follow-up. Material and Methods:We studied 74 (Age: 58 AE 9, Men: 71.6 %; BMI: 29.8 AE 5) diabetic patients (Type 2: 76 %) with Overt Diabetic Nephropathy (at inclusion: BP 155/89 mmHg, Creatinine 1.62 mg/dl, eGFR (MDRD): 59.2 ml/min/1.73 m2, HbA1c: 7.7 %, Proteinuria: 2.44 AE 1.3 gr/24 h) followed during 30 AE 4 months. After their inclusion and informed consent, all patients followed nephrologic and ophthalmologic controls every 6 months. VEGF levels were measured at entry and after 24-month follow-up. All patients received a multifactorial treatment based-on 32 mg BID Candesartan associated to an average of 3 antihypertensives agents (mainly diuretics (94.6 %)), statins (89%), antiplatelets (81%), insulin (78%) and oral antidiabetics (37.8 %). Analysis of data with SPSS 11.0 biostatistic program.